Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
Authors:
- 3 February 2006
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 49 (3) , 442-451
Abstract
In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin. The primary focus was changes in HbA1c; secondary focus was diurnal glucose profiles and symptomatic hypoglycaemia. In this investigator-initiated open, parallel-group clinical trial involving seven centres, 110 insulin-naive type 2 diabetic patients with poor glycaemic control (HbA1c ≥8.0%) on oral hypoglycaemic agents (90% using sulfonylurea plus metformin) were randomised to receive bedtime insulin glargine with metformin (G+MET) or bedtime NPH with metformin (NPH+MET) for 36 weeks. The patients were taught how to self-adjust their insulin dose and use a modem to send the results of home glucose monitoring to treatment centres. The goal was to achieve a fasting plasma glucose (FPG) of 4.0 to 5.5 mmol/l in both groups. During the last 12 weeks, FPGs averaged 5.75±0.02 and 5.96±0.03 mmol/l (p–1 day–1, NS) in the G+MET and NPH+MET groups, respectively. At 36 weeks, mean HbA1c was 7.14±0.12 and 7.16±0.14%, respectively (NS). Symptomatic, but not confirmed symptomatic, hypoglycaemia was significantly lower during the first 12 weeks in the G+MET group (4.1±0.8 episodes/patient-year) than in the NPH+MET group (9.0±2.3 episodes/patient-year, pp=0.002) throughout the 36-week study. With regard to baseline characteristics such as initial glycaemia or C-peptide, there was no difference between patients who achieved good glycaemic control (HbA1c p<0.01). Good glycaemic control can be achieved with both G+MET and NPH+MET. Use of G+MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinnertime hyperglycaemia compared with NPH+MET.Keywords
This publication has 24 references indexed in Scilit:
- Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular riskDiabetologia, 2004
- Sulfonylurea InadequacyDiabetes Care, 2002
- Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes MellitusAnnals of Internal Medicine, 1999
- Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes MellitusAnnals of Internal Medicine, 1999
- Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of DiseaseDiabetes, 1993
- Is Combination Sulfonylurea and Insulin Therapy Useful in NIDDM Patients?: A metaanalysisDiabetes Care, 1992
- Insulin plus a Sulfonylurea Agent for Treating Type 2 DiabetesAnnals of Internal Medicine, 1991
- Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy.Journal of Clinical Investigation, 1984
- Stimulation of Counterregulatory Hormonal Responses in Diabetic Man by a Fall in Glucose ConcentrationDiabetes, 1980